Abstract
Reversed-phase high-performance liquid chromatographic (HPLC) procedures are described for determining the stability of 2′,3′-dideoxyadenosine (DDA) in biological fluids at therapeutic dosages. The validated methodology uses both direct injection and solid-phase extraction techniques. Deamination of DDA to 2′,3′-dideoxyinosine (DDI) in plasma by adenosine deaminase was monitored by HPLC, and the identification of DDI verified by thermospray HPLC-mass spectrometry. This methodology should prove useful in future studies concerning the stability and metabolism of dideoxynucleosides.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Chromatography B: Biomedical Sciences and Applications
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
